PharmaResearch Co., Ltd. (KOSDAQ:214450)

Market Cap	2.87T -30.7%
Revenue (ttm)	565.48B +44.1%
Net Income	176.52B +59.1%
EPS	15,849.29 +49.3%
Shares Out	10.39M
PE Ratio	17.41
Forward PE	15.90
Dividend	3,700.00 (1.43%)
Ex-Dividend Date	Dec 29, 2025

Volume	95,990
Open	260,000
Previous Close	259,000
Day's Range	257,500 - 285,000
52-Week Range	255,000 - 713,000
Beta	0.46
Analysts	Buy
Price Target	516,214.29 (+87.03%)
Earnings Date	Aug 7, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 497
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214450

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Buy." The 12-month stock price target is ₩516,214, which is an increase of 87.03% from the latest price.

Price Target

₩516,214

(87.03% upside)

Analyst Consensus: Buy